lapatinib has been researched along with sumatriptan in 3 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (sumatriptan) | Trials (sumatriptan) | Recent Studies (post-2010) (sumatriptan) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 2,405 | 461 | 480 |
| Protein | Taxonomy | lapatinib (IC50) | sumatriptan (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | 0.0073 | |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | 0.0073 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.4497 | |
| Carboxypeptidase M | Homo sapiens (human) | 0.02 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.64 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.722 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.64 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.3091 | |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 0.0131 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 7.9433 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 3.9753 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.804 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.061 | |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | 5.5 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.64 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 0.0078 | |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | 0.5012 | |
| 5-hydroxytryptamine receptor 1D | Sus scrofa (pig) | 0.02 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.45 | |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | 0.0073 | |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | 0.0073 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 6.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and sumatriptan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for lapatinib and sumatriptan
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |